v3.25.1
Share-based compensation plan - Phantom shares plan ("PS") and Restricted Shares (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2025
BRL (R$)
shares
R$ / shares
shares
Dec. 31, 2024
BRL (R$)
shares
R$ / shares
Dec. 31, 2023
BRL (R$)
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Share-based compensation plans | R$ R$ 361,895,000 R$ 361,974,000  
PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 10,394,130 10,096,497  
Granted during of the year 2,010,686    
Cancelled 257,914    
Exercised (1) 1,455,139    
Available for completion 439,037    
Restricted stock, year one 2,304,845    
Restricted stock, year two 2,996,742    
Restricted stock, year three 2,793,916    
Restricted stock, year four 1,859,590    
Share-based compensation plans | R$ R$ 361,895,000 R$ 361,974,000 R$ 268,489,000
Increase Provision Share Based Payment | R$ 83,198,000 173,486,000  
Decrease Provision Share Based Payment | R$ R$ (83,277,000) R$ (80,001,000)  
Phantom Share Units Psus      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Phantom Share Units Psus | R$ / shares R$ 60.25 R$ 42.36  
Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 3,224,364 2,980,111  
Granted during of the year 363,811    
Exercised (1) 119,558    
Restricted stock, year one 348,417    
Restricted stock, year two 504,946    
Restricted stock, year three 431,331    
Restricted stock, year four 150,604    
Share-based compensation plans | R$ R$ 64,827,000 R$ 60,226,000 R$ 26,744,000
Increase Provision Share Based Payment | R$ 11,038,000 81,276,000  
Decrease Provision Share Based Payment | R$ R$ (6,437,000) (47,794,000)  
Grant Year 2020 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 38.50  
Number of other equity instruments outstanding in share-based payment arrangement 34,467 33,384  
Granted during of the year 1,083    
Available for completion 34,467    
Grant Year 2021 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 62.25  
Number of other equity instruments outstanding in share-based payment arrangement 531,809 874,480  
Granted during of the year 28,375    
Cancelled 13,046    
Exercised (1) 358,000    
Available for completion 404,570    
Restricted stock, year one 127,239    
Grant Year 2022 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 57.48  
Number of other equity instruments outstanding in share-based payment arrangement 2,495,773 3,461,437  
Granted during of the year 112,251    
Cancelled 98,593    
Exercised (1) 979,322    
Restricted stock, year one 2,148,353    
Restricted stock, year two 323,447    
Restricted stock, year three 23,973    
Grant Year 2022 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 53.81  
Number of other equity instruments outstanding in share-based payment arrangement 115,800  
Granted during of the year 3,758    
Exercised (1) 119,558    
Grant Year 2023 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 48.84  
Number of other equity instruments outstanding in share-based payment arrangement 2,992,558 3,052,179  
Granted during of the year 98,965    
Cancelled 95,361    
Exercised (1) 63,225    
Restricted stock, year one 29,253    
Restricted stock, year two 2,670,308    
Restricted stock, year three 292,997    
Grant Year 2023 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 51.41  
Number of other equity instruments outstanding in share-based payment arrangement 396,016 383,568  
Granted during of the year 12,448    
Restricted stock, year two 277,249    
Restricted stock, year three 118,767    
Grant Year 2024 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 56.53  
Number of other equity instruments outstanding in share-based payment arrangement 2,677,672 2,675,017  
Granted during of the year 86,665    
Cancelled 46,819    
Exercised (1) 37,191    
Restricted stock, year two 2,987    
Restricted stock, year three 2,476,946    
Restricted stock, year four 197,739    
Grant Year 2024 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 55.77  
Number of other equity instruments outstanding in share-based payment arrangement 2,561,252 2,480,743  
Granted during of the year 80,509    
Restricted stock, year one 348,417    
Restricted stock, year two 227,697    
Restricted stock, year three 312,564    
Grant Year 2025 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 60.53  
Number of other equity instruments outstanding in share-based payment arrangement 1,661,851  
Granted during of the year 1,683,347    
Cancelled 4,095    
Exercised (1) 17,401    
Restricted stock, year four 1,661,851    
Grant Year 2025 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 61.39  
Number of other equity instruments outstanding in share-based payment arrangement 267,096  
Granted during of the year 267,096    
Restricted stock, year one    
Restricted stock, year two    
Restricted stock, year three    
Restricted stock, year four 150,604